HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Meyer, M. Articles by Woloszczuk, W. Search for Related Content PubMed PubMed Citation Articles by Meyer, M. Articles by Woloszczuk, W. Related Collections Endocrinology and Metabolism

Urinary and plasma urodilatin measured by a direct RIA using a highly specific antiserum

¹ Niedersächsisches Institut für Peptid-Forschung GmbH (IPF), Feodor-Lynen-Strasse 31, 30625 Hannover, Germany.

² Immundiagnostik GmbH, Wiesenstrasse 4, 64625 Bensheim, Germany.

³ Universitätsklinik Heidelberg, Innere Medizin III, Kardiologie, Bergheimer Strasse 58, 69115 Heidelberg, Germany.

⁴ Biomedica GmbH, Divischgasse 4, 1210 Vienna, Austria.

⁵ Ludwig-Boltzmann-Institut für Experimentelle Endokrinologie, 1090 Vienna, Austria.
^a Author for correspondence. Fax 49-6251-849430; e-mail immundiagnostik{at}t-online.de; Internet.Immundiagnostik.com.

Urodilatin (95–126) (URO) appears to play a major physiologic role in fluid homeostasis and produces major changes when administered intravenously. Here we describe a monospecific, high-affinity antiserum against URO with no cross-reactivity (<0.01%) against the structural highly homologous atrial natriuretic peptide 99-126 (ANP-99-126), ANP analogs, and related peptides such as brain natriuretic peptide. A competitive RIA was developed, based on this antiserum. Urine samples with or without ethanol extraction and plasma samples without pretreatment were analyzed by the RIA, which had a detection limit of 10.5 ng/L, a linear measuring range between 10.5 and 1000 ng/L, and recoveries of 93–102% in urine and 90–104% in plasma. The intraassay CVs were 8.2% and 8.1% for urine samples with 269 and 669 ng/L URO; the interassay CV was 9.7% at 839 ng/L. Using this assay, we present URO data for urine from healthy volunteers receiving low and routine sodium diets and from clinical urine specimens; we also present pharmacokinetic data for URO in plasma from patients suffering from bronchial asthma and treated by URO infusion.

The following articles in journals at HighWire Press have cited this article:

				H. H. Chen, A. Cataliotti, J. A. Schirger, F. L. Martin, and J. C. Burnett Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2005; 288(5): R1093 - R1097. [Abstract] [Full Text] [PDF]

				M. Heringlake, C. Heide, L. Bahlmann, W. Eichler, H. Pagel, P. Schmucker, R. Wergeland, F. P. Armbruster, and S. Klaus Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers J Appl Physiol, July 1, 2004; 97(1): 173 - 179. [Abstract] [Full Text] [PDF]